A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
Phase of Trial: Phase I/II
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Galinpepimut S (Primary) ; Pembrolizumab (Primary)
- Indications Acute myeloid leukaemia; Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Sellas Life Sciences Group
- 20 Dec 2018 Planned End Date changed from 15 Jan 2021 to 28 Feb 2021.
- 20 Dec 2018 Planned primary completion date changed from 15 Jul 2020 to 31 Aug 2020.
- 20 Dec 2018 Status changed from not yet recruiting to recruiting.